SomnoMed Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Amrita Blickstead

Chief executive officer

AU$91.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	4yrs
CEO ownership	0.5%
Management average tenure	5yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Amrita Blickstead

4yrs

Tenure

AU$91,206

Compensation

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Amrita Blickstead	Co-CEO & Executive Director	no data	AU$91.21k	0.49% A$ 231.2k
Karen Borg	Co-CEO & Executive Director	no data	AU$91.21k	0.22% A$ 103.2k
Mark Harding	Vice President of Global Marketing	5.1yrs	AU$505.38k	0.067% A$ 31.3k
Matthew Conlon	Executive VP of Sales & Marketing - North America	4.8yrs	AU$623.78k	0.039% A$ 18.4k
Marco Van Kleef	Vice President of Marketing & Sales - Europe	no data	AU$525.51k	no data
Darren Collins	Chief Financial Officer	less than a year	no data	no data
Terence Flitcroft	Company Secretary	29.6yrs	AU$10.56k	no data
Christopher Bedford	Vice President of Global Production and Product Development	no data	AU$205.30k	no data

5.0yrs

Average Tenure

Experienced Management: RJV's management team is considered experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Amrita Blickstead	Co-CEO & Executive Director	4yrs	AU$91.21k	0.49% A$ 231.2k
Karen Borg	Co-CEO & Executive Director	3.8yrs	AU$91.21k	0.22% A$ 103.2k
Michael Gordon	Non-Executive Director	4yrs	AU$92.34k	0.10% A$ 48.8k
Iven Klineberg	Member of the Medical Advisory Board	no data	no data	no data
J. Gerschman	Member of the Medical Advisory Board	no data	no data	no data
Peter Cistulli	Chairman of the Medical Advisory Board	no data	no data	no data
Gaetano Russo	Chairman of the Board	4yrs	AU$184.68k	0.64% A$ 301.2k
Hamish Corlett	Non-Executive Director	6.3yrs	AU$91.21k	no data

4.0yrs

Average Tenure

Experienced Board: RJV's board of directors are considered experienced (4 years average tenure).

SomnoMed Management

Management criteria checks 3/4

Key information

Recent management updates

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Somnomed Limited Announces Executive Changes

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

Recent updates

New major risk - Shareholder dilution

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

New major risk - Share price stability

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.056 loss in FY 2022)

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.056 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

Full year 2022 earnings released: AU$0.056 loss per share (vs AU$0.014 loss in FY 2021)

SomnoMed Limited Provides Earnings Guidance for the Year 2023

No independent directors

Global CEO recently sold €54k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

SomnoMed Introduces Rest Assure

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought €315k worth of stock

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought €50k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Forecast to breakeven in 2023

Non-Executive Director recently bought €51k worth of stock

New 90-day low: €1.15

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

Full year earnings released - €0.0069 loss per share

New 90-day high: €1.28

New 90-day high - €0.94

Chairman of the Board recently bought €126k worth of stock

Earnings released

SomnoMed Limited to Report Fiscal Year 2020 Results on Aug 24, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure